Skip to content
value.today

X4 Pharmaceuticals, Inc.

XFOR
$332 Mmarket cap on Oct 28, 2026+138.8% since Jan 2024
Compare
World rank
#14,362
Revenue
$35 M
For year ending December-2025
Net income
$-79 M
-225.6% margin
SEC filing
Employees
45
As of December 31, 2025
SEC filing

X4 Pharmaceuticals, Inc. in brief

X4 Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in Boston, Massachusetts, USA. It was founded in 2010. Its market value was $332 M on 28 October 2026, which makes it the 14,362nd largest listed company in the world and the 2,811th largest in the USA on this site. In the year to December 2025 it had sales of $35 M and a net loss of $79 M. It employs about 45 people. Its largest product and service lines by sales in 2025 were License and other revenue (81%). Its shares trade under the symbol XFOR (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About X4 Pharmaceuticals, Inc.

We are a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners.

Our primary asset is mavorixafor, a small molecule delivered in a capsule for oral dosing as a selective antagonist of the chemokine receptor, CXCR4. We have one commercially approved product, XOLREMDI® (mavorixafor), which has received accelerated approval in the United States from the FDA for use as an oral, once-daily therapy in patients 12 years of age and older with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, to increase the number of circulating mature neutrophils and lymphocytes. WHIM syndrome is a rare combined primary immunodeficiency and chronic neutropenic disorder. Mavorixafor is currently being studied in a pivotal clinical trial in chronic neutropenia.

From the company's annual report filed with the US SEC: read the report

X4 Pharmaceuticals, Inc. timeline

5 events, 2010–2025
  1. 2010
  2. 🏁
    · approximate
    Founded
  3. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  4. 2017
  5. 🔔
    Initial public offering as Arsanis, Inc.
    Final prospectus filed with the SEC on 17 November 2017; shares registered for exchange trading on 15 November 2017.
  6. 2019
  7. ✎
    Renamed X4 Pharmaceuticals, Inc
    Formerly Arsanis, Inc..
  8. 2025
  9. 💰
    Record revenue of $35 million
    FY2025, the highest of the 3 years on record.

Events of X4 Pharmaceuticals, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$113 M$226 M$339 M$451 M2020202120222023202420252026

World rank over time

▲ up 3,231 places since 2020
2020-01-01: #17628#17,62820202021-01-01: #18004#18,00420212022-01-07: #25469#25,46920222022-12-25: #21362#21,36220222023-07-30: #16100#16,10020232024-01-05: #19765#19,76520242026-03-08: #8150#8,15020262026-08-01: #12958#12,95820262026-10-28: #14397#14,3972026

Rank in USA: #3,510 (Jan 2020) · #3,662 (Jan 2021) · #4,776 (Jan 2022) · #4,244 (Dec 2022) · #3,270 (Jul 2023) · #3,486 (Jan 2024) · #1,466 (Mar 2026) · #2,637 (Aug 2026) · #2,815 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
9.5×
Price / book
1.8×
Free cash flow yield
-25.8%
Net margin
-225.6%
Operating margin
-247.5%
Return on equity
-42.5%
Liabilities / assets
35.9%
Net debt
$-142M
Revenue growth
+1250.4%
R&D / revenue
207.1%
Revenue per employee
$780 K
Profit per employee
$-1.8 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-33M—FY18Fiscal year ending Dec 2019: revenue —, net income $-53M—FY19Fiscal year ending Dec 2020: revenue $3M, net income $-62M$3MFY20Fiscal year ending Dec 2021: revenue —, net income $-89M—FY21Fiscal year ending Dec 2022: revenue —, net income $-94M—FY22Fiscal year ending Dec 2023: revenue —, net income $-101M—FY23Fiscal year ending Dec 2024: revenue $3M, net income $-37M$3MFY24Fiscal year ending Dec 2025: revenue $35M, net income $-79M$35MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$35M+1250.4%$-87M$-79M-225.6%
Dec 2024$3M—$-36M$-37M-1440.4%
Dec 2023——$-108M$-101M—
Dec 2022——$-88M$-94M—
Dec 2021——$-85M$-89M—
Dec 2020$3M—$-60M$-62M-2071.0%
Dec 2019——$-52M$-53M—
Dec 2018——$-29M$-33M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-86M$0M$-86M$-1.87—
Dec 2024$-131M$0M$-131M$-5.59—
Dec 2023$-97M$0M$-97M$-17.07—
Dec 2022$-77M$0M$-77M$-1.52—
Dec 2021$-71M$1M$-72M$-3.99—
Dec 2020$-59M$1M$-60M$-3.09—
Dec 2019$-48M$0M$-48M$-4.63—
Dec 2018$-25M$0M$-25M$-79.15—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-40M—Dec ’24Three months to Mar 2025: revenue $29M, net income $0M$29MMar ’25Three months to Jun 2025: revenue $2M, net income $-26M$2MJun ’25Three months to Sep 2025: revenue $2M, net income $-30M$2MSep ’25Three months to Dec 2025 (from the annual report): revenue $3M, net income $-24M$3MDec ’25Three months to Mar 2026: revenue $3M, net income $-20M$3MMar ’26Three months to Jun 2026: revenue $9M, net income $-16M$9MJun ’26Three months to Sep 2026: revenue $3M, net income $-20M$3MSep ’26

Latest quarter to Sep 2026: revenue $3M (+75.0% on a year earlier), net income $-20M. Lighter bars: fourth quarters worked out from the annual report.

SEC filings

Official filings of X4 Pharmaceuticals, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$35 M
Operating income
$-87 M
Net income
$-79 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$290 M
Total liabilities
$104 M
Total equity
$186 M

As of December-2025

Top 96 institutional investors in X4 Pharmaceuticals, Inc.#

As of Sep 30, 2026
96 institutions held 105.0 M shares (more than all shares outstanding: lent and sub-advised shares are reported by more than one filer) on Sep 30, 2026. The ten largest hold 69.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in X4 Pharmaceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Morgan Stanley10,996,210+1,534,931 (+16.22%)10.77%$32 MNov 13, 2026
2Empery Asset Management, LP9,725,509+2,794,918 (+40.33%)9.52%$28 MNov 16, 2026
3Bain Capital Life Sciences Investors, LLC7,967,4540 (0.00%)7.80%$23 MNov 16, 2026
4Venrock Adviser, LLC7,644,072+5,709,819 (+295.20%)7.49%$22 MNov 16, 2026
5Saturn V Capital Management LP7,366,442+393,099 (+5.64%)7.21%$21 MNov 16, 2026
6Perceptive Advisors LLC7,350,491-583,000 (-7.35%)7.20%$21 MNov 16, 2026
7BlackRock, Inc.5,854,521+299,615 (+5.39%)5.73%$17 MNov 13, 2026
8FMR LLC5,490,787-2,830,870 (-34.02%)5.38%$16 MNov 10, 2026
9Deep Track Capital, LP4,501,684-1,377,073 (-23.42%)4.41%$13 MNov 16, 2026
10Kalehua Capital Management LLC3,722,840-3,722,840 (-50.00%)3.65%$11 MNov 13, 2026
11Vanguard Capital Management LLC3,558,591-157,268 (-4.23%)3.48%$10 MNov 13, 2026
12Rosalind Advisors, Inc.3,214,7660 (0.00%)3.15%$9 MNov 16, 2026
13Trails Edge Capital Partners, LP2,571,4780 (0.00%)2.52%$7 MNov 16, 2026
14Nantahala Capital Management, LLC2,449,468-2,449,468 (-50.00%)2.40%$7 MNov 13, 2026
15Blackstone Inc.2,427,080-254,842 (-9.50%)2.38%$7 MNov 16, 2026
16Braidwell LP2,344,822-577,932 (-19.77%)2.30%$7 MNov 16, 2026
17Goldman Sachs Group Inc2,335,042+1,418,506 (+154.77%)2.29%$7 MNov 16, 2026
18Affinity Asset Advisors, LLC2,062,500+1,917,500 (+1322.41%)2.02%$6 MNov 13, 2026
19Geode Capital Management, LLC2,047,281-50,766 (-2.42%)2.00%$6 MNov 6, 2026
20State Street Corp1,730,123+434,106 (+33.50%)1.69%$5 MNov 12, 2026
21BVF Inc/il1,576,624-657,118 (-29.42%)1.54%$5 MNov 16, 2026
22Samsara Biocapital, LLC1,347,723-47,864 (-3.43%)1.32%$4 MNov 16, 2026
23Woodline Partners LP1,001,0950 (0.00%)0.98%$3 MNov 16, 2026
24Northern Trust Corp627,744-25,105 (-3.85%)0.61%$2 MNov 16, 2026
25Vanguard Portfolio Management LLC572,106+29,978 (+5.53%)0.56%$2 MNov 13, 2026
Show all 96: investors 26 to 96
Institutional investors 26 to 96 in X4 Pharmaceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Vanguard Fiduciary Trust Co512,811-59,227 (-10.35%)0.50%$1 MNov 13, 2026
27Verdad Advisers, LP323,166-28,927 (-8.22%)0.32%$1 MNov 16, 2026
28Wellington Management Group LLP289,231+237,431 (+458.36%)0.28%$1 MNov 16, 2026
29Charles Schwab Investment Management Inc263,282+18 (+0.01%)0.26%$1 MNov 16, 2026
30Integral Health Asset Management, LLC250,000New0.24%$1 MNov 16, 2026
31Russell Investments Group, Ltd.213,258+206,080 (+2870.99%)0.21%$1 MNov 6, 2026
32Bank of New York Mellon Corp204,991+8,651 (+4.41%)0.20%$1 MNov 5, 2026
33Citadel Advisors LLC150,205New0.15%$0 MNov 16, 2026
34Stonepine Capital Management, LLC150,000-74,989 (-33.33%)0.15%$0 MNov 13, 2026
35Alps Advisors Inc130,424+34,698 (+36.25%)0.13%$0 MNov 3, 2026
36Invesco Ltd.117,230+20,458 (+21.14%)0.11%$0 MNov 12, 2026
37Renaissance Technologies LLC115,524+97,424 (+538.25%)0.11%$0 MNov 12, 2026
38American Century Companies Inc113,736+38,941 (+52.06%)0.11%$0 MNov 12, 2026
39Nuveen, LLC111,057+3,668 (+3.42%)0.11%$0 MNov 10, 2026
40Prudential Financial Inc109,705+97,205 (+777.64%)0.11%$0 MNov 16, 2026
41Susquehanna Portfolio Strategies, LLC102,223+14,941 (+17.12%)0.10%$0 MNov 16, 2026
42XTX Topco Ltd100,745New0.10%$0 MNov 16, 2026
43Rhumbline Advisers94,984-97 (-0.10%)0.09%$0 MNov 10, 2026
44Point72 Asset Management, L.P.93,565+52,493 (+127.81%)0.09%$0 MNov 16, 2026
45Squarepoint Ops LLC83,488+16,410 (+24.46%)0.08%$0 MNov 9, 2026
46Bank Of America Corp /de/70,237+23,376 (+49.88%)0.07%$0 MNov 16, 2026
47EntryPoint Capital, LLC70,147New0.07%$0 MNov 13, 2026
48Deutsche Bank AG\68,976-9,909 (-12.56%)0.07%$0 MNov 6, 2026
49Algert Global LLC67,553New0.07%$0 MNov 17, 2026
50Price T Rowe Associates Inc /MD/66,3790 (0.00%)0.07%$0 MNov 16, 2026
51UBS Group AG49,253-8,790 (-15.14%)0.05%$0 MNov 10, 2026
52Palumbo Wealth Management LLC48,373-18,743 (-27.93%)0.05%$0 MNov 13, 2026
53Citigroup Inc42,762-27,350 (-39.01%)0.04%$0 MNov 4, 2026
54Jpmorgan Chase & Co41,369+7,817 (+23.30%)0.04%$0 MNov 12, 2026
55Barclays PLC39,770+20,331 (+104.59%)0.04%$0 MNov 6, 2026
56MetLife Investment Management, LLC39,235-8,734 (-18.21%)0.04%$0 MNov 16, 2026
57MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.39,094+2,021 (+5.45%)0.04%$0 MNov 16, 2026
58Vanguard Global Advisers, LLC33,393+416 (+1.26%)0.03%$0 MNov 13, 2026
59Two Sigma Investments, LP28,488+9,062 (+46.65%)0.03%$0 MNov 16, 2026
60Police & Firemen's Retirement System of New Jersey23,8460 (0.00%)0.02%$0 MNov 9, 2026
61Manufacturers Life Insurance Company, The23,828+1,745 (+7.90%)0.02%$0 MNov 13, 2026
62Stifel Financial Corp20,291+1,772 (+9.57%)0.02%$0 MNov 12, 2026
63BNP Paribas Financial Markets18,710+2,326 (+14.20%)0.02%$0 MNov 12, 2026
64Susquehanna International Group, LLP17,583+3,533 (+25.15%)0.02%$0 MNov 16, 2026
65Voya Investment Management LLC16,665+827 (+5.22%)0.02%$0 MNov 10, 2026
66New York State Common Retirement Fund16,5000 (0.00%)0.02%$0 MNov 17, 2026
67Wells Fargo & Company/mn16,309-51,403 (-75.91%)0.02%$0 MNov 16, 2026
68Alliancebernstein L.P.14,5800 (0.00%)0.01%$0 MNov 16, 2026
69Voleon Capital Management LP14,078New0.01%$0 MNov 16, 2026
70Caxton Corp13,534-2,023 (-13.00%)0.01%$0 MNov 16, 2026
71Creative Planning11,308-2,564 (-18.48%)0.01%$0 MNov 2, 2026
72ProShare Advisors LLC10,533-55 (-0.52%)0.01%$0 MOct 29, 2026
73WINTON GROUP Ltd10,200-4,200 (-29.17%)0.01%$0 MNov 12, 2026
74Pettinga Financial Advisors LLC10,0000 (0.00%)0.01%$0 MOct 13, 2026
75Legal & General Group Plc7,8580 (0.00%)0.01%$0 MNov 16, 2026
76Ameritas Investment Partners, Inc.7,3380 (0.00%)0.01%$0 MNov 13, 2026
77Tower Research Capital LLC (TRC)4,959-2,786 (-35.97%)0.00%$0 MNov 16, 2026
78Royal Bank Of Canada4,612+2,053 (+80.23%)0.00%$0 MNov 16, 2026
79PNC Financial Services Group, Inc.1,924+165 (+9.38%)0.00%$0 MNov 6, 2026
80Sterling Capital Management LLC1,652+23 (+1.41%)0.00%$0 MOct 22, 2026
81California State Teachers Retirement System1,1130 (0.00%)0.00%$0 MNov 13, 2026
82Farther Finance Advisors, LLC789New0.00%$0 MOct 8, 2026
83Group One Trading LLC7120 (0.00%)0.00%$0 MNov 10, 2026
84Bleichroeder LP5950 (0.00%)0.00%$0 MNov 13, 2026
85Simplex Trading, LLC424New0.00%$0 MNov 4, 2026
86UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC389New0.00%$0 MNov 16, 2026
87GAMMA Investing LLC385New0.00%$0 MOct 8, 2026
88Blue Trust, Inc.2840 (0.00%)0.00%$0 MOct 15, 2026
89Rockefeller Capital Management L.P.188+155 (+469.70%)0.00%$0 MNov 13, 2026
90Osaic Holdings, Inc.57New0.00%$0 MNov 12, 2026
91National Bank Of Canada /fi/11New0.00%$0 MNov 16, 2026
92SBI Securities Co., Ltd.11+2 (+22.22%)0.00%$0 MOct 22, 2026
93Caitong International Asset Management Co., Ltd11-19 (-63.33%)0.00%$0 MOct 29, 2026
94HighMark Wealth Management LLC60 (0.00%)0.00%$0 MNov 17, 2026
95Arax Advisory Partners3New0.00%$0 MNov 12, 2026
96Root Financial Partners, LLC1New0.00%$0 MOct 21, 2026

Mutual funds holding X4 Pharmaceuticals, Inc.#

64 funds hold shares worth $97 M (about 21.7% of the company). Since their previous reports 50 added shares and 4 sold, buying $25 M net.
Mutual funds holding X4 Pharmaceuticals, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC3.39 M$13 M3.3%0.15%no changeJul 31, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.2.60 M$12 M2.5%<0.01%+4.6%Jun 30, 2026
🇺🇸 Inception PortfolioMorgan Stanley Investment Management Inc.2.31 M$11 M2.3%3.8%−1.1%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.91 M$9 M1.9%0.01%newJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC1.82 M$8 M1.8%1.8%no changeJun 30, 2026
🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC1.69 M$7 M1.7%0.15%no changeJul 31, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC1.43 M$6 M1.4%0.12%−15%May 31, 2026
🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC1.34 M$5 M1.3%0.24%no changeJul 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.03 M$5 M1.0%<0.01%+12%Jun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors758,220$4 M0.74%0.02%newJun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC884,763$4 M0.87%0.01%newJul 31, 2026
🇺🇸 Fidelity Small Cap Stock FundFidelity Management & Research Company LLC504,600$2 M0.49%0.15%newJul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC422,860$2 M0.41%<0.01%+4.4%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors271,214$1 M0.27%0.08%newJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.196,530$1 M0.19%0.01%newJul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC167,464$1 M0.16%<0.01%no changeMay 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC151,139$1 M0.15%0.01%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC124,251$1 M0.12%<0.01%−11%May 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC112,837$1 M0.11%0.02%newJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC107,389$0 M0.11%0.01%newJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC86,641$0 M0.08%0.01%newJun 30, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC79,833$0 M0.08%0.03%newJul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation59,100$0 M0.06%0.01%newJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.66,731$0 M0.07%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC56,741$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust46,744$0 M0.05%<0.01%newMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.42,532$0 M0.04%<0.01%−13%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.42,268$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.41,980$0 M0.04%0.01%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC38,483$0 M0.04%0.01%newJul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.29,000$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC27,197$0 M0.03%0.01%newJun 30, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC30,166$0 M0.03%<0.01%+51%Jul 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC23,222$0 M0.02%0.01%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC22,814$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC18,231$0 M0.02%0.04%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS17,857$0 M0.02%0.01%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC16,839$0 M0.02%0.01%newJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.12,703$0 M0.01%0.01%newJun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC12,524$0 M0.01%0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC14,446$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.12,192$0 M0.01%0.01%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC10,917$0 M0.01%0.01%newJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC10,068$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC11,344$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC9,468$0 M<0.01%0.01%newJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.8,775$0 M<0.01%<0.01%+14%Jul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management7,338$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC6,449$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC6,376$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS7,216$0 M<0.01%0.01%newJul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC5,770$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC6,060$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC4,860$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC4,860$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC3,654$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC3,666$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC2,817$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.2,041$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,505$0 M<0.01%<0.01%+3.6%Jun 30, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.1,031$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC471$0 M<0.01%<0.01%+11%Jul 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC1$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC1$0 M<0.01%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 64 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at X4 Pharmaceuticals, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$12 K
1 purchase, 1 insider
Sold, 12 months
$463 K
5 sales, 3 insiders
Net, 12 months
-$451 K
open market only
Insiders on file
37
since
$250 K-$407 K$0Nov 2023: bought $0 (0 trades), sold $407 K (6 trades)Nov 23Feb 2024: bought $0 (0 trades), sold $54 K (4 trades)Mar 2024: bought $0 (0 trades), sold $116 K (4 trades)MarMay 2024: bought $15 K (1 trades), sold $0 (0 trades)Sep 2024: bought $0 (0 trades), sold $2 K (1 trades)SepOct 2024: bought $0 (0 trades), sold $365 K (6 trades)Nov 2024: bought $5 K (1 trades), sold $12 K (1 trades)NovJan 2025: bought $0 (0 trades), sold $96 K (5 trades)May 2025: bought $3 K (1 trades), sold $0 (0 trades)MayOct 2025: bought $250 K (1 trades), sold $0 (0 trades)May 2026: bought $0 (0 trades), sold $73 K (1 trades)MayJun 2026: bought $0 (0 trades), sold $36 K (1 trades)Aug 2026: bought $0 (0 trades), sold $320 K (2 trades)AugOct 2026: bought $12 K (1 trades), sold $34 K (1 trades)
Bought (open market)Sold (open market)Hover a month for the totals
X4 Pharmaceuticals, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Adam R. CraigExecutive Chairman, DirectorBuy+4,600$2.583$12 K333,251Form 4
filed David KirskeChief Financial OfficerSell-11,767$2.860$34 K155,983Form 4
filed John VolponePresidentSell-24,576$4.440$109 K265,305Form 4
filed Adam R. CraigExecutive Chairman, DirectorSell-47,436$4.440$211 K328,651Form 4
filed David KirskeChief Financial OfficerSell-8,543$4.260$36 K167,750Form 4
filed David KirskeChief Financial OfficerSell-16,961$4.290$73 K176,293Form 4
filed Adam R. CraigExecutive Chairman, DirectorBuy+86,206$2.900$250 K376,087Form 4
filed Adam R. CraigExecutive Chairman, DirectorGrant or award+289,881——289,881Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: X4 Pharmaceuticals, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
8.0 M
8.8% of shares · 10.86 days to cover
Buybacks, Q1 2023
$0.4M
Q3 2022
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-30.03 reverse split ; 1-for-6 reverse split ; 1-for-3.41 reverse split ; 1-for-6 reverse split

X4 Pharmaceuticals, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q1 2023Q3 2022$0.4M
Q4 2022Q4 2022$0M
Q4 2021Q4 2021$0M
Q4 2020Q4 2021$0M

Trading halts

  • 2025-10-24 13:39 UTC, code LUDP, resumed 13:44 UTC
  • 2025-08-12 19:37 UTC, code T3, resumed 11:30 UTC
  • 2025-04-25 23:50 UTC, code T3, resumed 13:00 UTC
  • 2025-01-29 19:49 UTC, code LUDP, resumed 19:54 UTC

Fails to deliver

  • : 21 shares at $3.25
  • : 9 shares at $3.24
  • : 823 shares at $3.20
  • : 2,835 shares at $2.75
  • : 88 shares at $2.45

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

X4 Pharmaceuticals, Inc. scorecard#

Passes 4 of the 16 checks that could be worked out: strongest in financial health (3 of 5), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.8×Price to book 1.8× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median9.4×Price to sales 9.4× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-25.8%Free cash flow is -25.8% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.87 vs -5.59Diluted EPS -1.87 in fiscal 2025 against -5.59 the year before (report's currency).
    • ✗Net income higher than five years earlier-$79 M-$79 M in fiscal 2025 against -$62 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 4
    • ✗Profitable in the newest year-$79 MNet income -$79 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-247.4%-247.4% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-76.0%-76.0% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health3 of 5
    • ✓Short-term assets cover short-term liabilities10.2×Current ratio 10.15 at the end of fiscal 2025.
    • ✓Debt below equity0.4×Debt to equity 0.40 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $142 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-0.85Z-score -0.85 (distress zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from X4 Pharmaceuticals, Inc.'s statements, beside the median of Biotechnology.

X4 Pharmaceuticals, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-247.5%-60.5%
Net margin-225.6%-68.9%
Return on equity-76.0%-61.0%
Debt to equity0.40×0.26×
Free cash flow margin-243.9%-61.5%

4of 9on the Piotroski tests of financial strength

  • Net loss of $79 million, the 10th loss-making year in a row.
  • Free cash flow was negative: -$86 million.
  • More cash than debt: net cash of $142 million.

X4 Pharmaceuticals, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

X4 Pharmaceuticals, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue352.6r0003.000r——
Cost of revenue5.80.800——————
Research and development7382726151423020r17r18
General and administrative446236272521188.7r5.2r6.5
Operating expenses——1088885635229r22r24
Total costs and expenses—3910888——————
Operating income−87−36−108−88−85−60−52−29r−22r−24
Interest and finance income4.65.84.60.20.00.31.20.2r0.1r—
Interest expense and finance costs8.98.85.84.03.62.72.10.7r0.5r2.5
Other non-operating income (expense)7.7−0.76.4−6.3−3.6−2.1−1.1−4.2r0.3r1.4
Income before tax−79−37−101−94−89−62−53−33r−22r−23
Income tax0.00.30.10.00.00.100——
Net income including minority interests—−37−101−94−89−62−53−33−22—
Net income attributable to shareholders−79−37−101−94−89−62−53−33r−22r−23
Earnings per share, basic-1.87-5.59r-17.07r-1.52-3.99-3.09-4.63-79.15r-54.58r-44.79
Earnings per share, diluted-1.87-5.59r-17.07r-1.52-3.99-3.09-4.63-79.15r-54.58r-44.79
Shares, weighted average (basic)426.7r5.9r64r26r20————
Shares, weighted average (diluted)426.7r5.9r64r26r20120.5r0.5r0.5
Balance sheet
Cash and cash equivalents217569912282791268.1r27r15r
Receivables0.61.10———0———
Inventory—2.80———————
Other current assets3.55.67.35.85.33.71.11.2r0.3—
Current assets26211212212988831299.3r80—
Property, plant and equipment0.20.80.71.11.51.20.40.2r0.4—
Right-of-use (leased) assets1.44.15.77.28.78.02.0———
Goodwill171717171727270——
Other intangible assets9.3100———————
Total assets2901461471561171231619.9r81—
Accounts payable5.78.68.97.84.33.12.13.0r1.9—
Debt due within a year——01.30.8001.7——
Current liabilities2633232214129.47.9r11—
Long-term debt——55323333208.3——
Lease liabilities (non-current)01.42.63.64.84.51.9———
Total liabilities104124968253503122r23—
Retained earnings−595−515−478−377−283−194−132−79r−92—
Shareholders' equity1862251746473129−77r−45r−23r
Total liabilities and equity2901461471561171231619.9r81—
Shares outstanding915.7r1671222816160.4r14—
Cash-flow statement
Depreciation and amortization1.30.80.40.50.50.40.10.1r0.1r0.3
Share-based compensation4.38.28.75.26.25.42.10.8r0.5r0.6
Cash from operating activities−86−131−97−77−71−59−48−25r−21r−22
Capital expenditure0−0.3−0.1−0.1−0.6−1.4−0.20r−0.4r−0.1
Intangible assets bought—−7.000——————
Cash from investing activities8.267−15−0.1−0.6−1.4270r−0.4r−0.1
Debt issued————————0.70.5
Debt repaid00−2.1−0.800−9.4−6.4r0r−0.3
Shares issued239060———————
Shares bought back——00−2.000———
Cash from financing activities239208911774121416.9r33r18
Exchange-rate effect on cash0.2−0.20.1−0.1−0.30.4−0.30r0r−0.1
Change in cash161−44−23402.4−47120−19r12r−3.7
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What X4 Pharmaceuticals, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • License and other revenue$29 M81%
  • Product revenue, net(total)$7 M19%

Business segments

  • Reportable$35 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at X4 Pharmaceuticals, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$6.7 M
Other top executives, average
$5.6 M
the CEO earned 1.2× this
$100 invested is now
$13
X4 Pharmaceuticals, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chief executive$6.7 M$16.3 M$5.6 M$13
2024Dr. Ragan$2.1 M$1.4 M$1.2 M$74
2023Dr. Ragan$2.0 M$1.3 M$1.4 M$84

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at X4 Pharmaceuticals, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Restructuring 2 · Directors and officers 6 · Material agreement 6 · Agreement ended 1 · New debt 1 · Unregistered share sale 3 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 5

X4 Pharmaceuticals, Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreementAgreement endedNew debtUnregistered share sale8-K
Directors and officers8-K
Directors and officersShareholder vote8-K/A
Directors and officersShareholder vote8-K
Results announced8-K
Material agreement8-K
RestructuringDirectors and officers8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Directors and officersMaterial agreementUnregistered share sale8-K
Material agreement8-K
Shareholder vote8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Shareholder vote8-K
Results announced8-K
Restructuring8-K
Material agreement8-K
Results announced8-K
Delisting notice8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 8, 2026

Acquisitions and funding#

5 private funding rounds before listing

Private share sales · funding history

Private share sales of X4 Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2025$85 MPrivate placement after listing$50 to $250 million18equity, optionsSEC
May 2023$65 MPrivate placement after listing$50 to $250 million22equity, optionsSEC
Jul 2022$56 MPrivate placement after listing$50 to $250 million23equity, optionsSEC
Nov 2017$20 MNo. 5$10 to $50 million1equitySEC
Apr 2017$46 MNo. 4$10 to $50 million18equitySEC
Apr 2016$15 MNo. 3$10 to $50 million10equity, debtSEC
Jul 2013$20 MNo. 2$10 to $50 million8equitySEC
Jan 2011$10 MNo. 1$2 to $10 million7equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at X4 Pharmaceuticals, Inc.#

1 labor condition applications certified in fiscal 2022 for 1 positions, at a median wage of $340 K a year.

Certified, FY2022
1
#1,996 among companies on value.today
Worker positions
1
Median wage offered
$340 K
a year, full-time
Applications filed
1
X4 Pharmaceuticals, Inc.: most frequent H-1B job titles in fiscal 2022
Job titlePositionsMedian wage offered
Executive Medical DirectorMedical Scientists, Except Epidemiologists1$340 K

Where: Boston, MA 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as X4 Pharmaceuticals, Inc.

FDA drug approvals: X4 Pharmaceuticals, Inc.#

1 approved applications held, 1 of them new molecular entities; 1 approvals and 0 new uses in 2024.

Approvals held
1
New molecular entities
1
New uses approved
0
efficacy supplements
Generics
0
1 new drugs, 0 biologics
X4 Pharmaceuticals, Inc.: latest FDA approvals
ApprovedDrugKind
2024-04-26Xolremdinew moleculeMavorixafor · NDA218709New drug (NDA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (X4 PHARMS), so they follow acquisitions

Layoffs at X4 Pharmaceuticals, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
43
2025–2025
Latest
—
2025-09-15
X4 Pharmaceuticals, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2025·43··········43
X4 Pharmaceuticals, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
50% of workforceRestructuring planSEC 8-K“As part of this initiative, the Company will reduce its workforce by approximately 50%, a step anticipated to result in annualized cost savings of approximately $13 million.”Filing
43 people (30% of workforce)Restructuring planSEC 8-K“In connection with this shift in operational focus and strategic restructuring, the Company expects to implement a net reduction of its employee headcount by 43 employees, or appro…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How X4 Pharmaceuticals, Inc. compares in Biotechnology

  • Market cap$332 M · higher than 52% of 726
  • Revenue$35 M · higher than 55% of 647
  • Net margin-225.6% · higher than 25% of 408
  • Revenue growth1250.4% · higher than 98% of 438
  • Price / sales9.4× · lower than 45% of 339
  • Price / book1.8× · lower than 61% of 534
  • FCF yield-25.8% · higher than 38% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
X4 Pharmaceuticals, Inc.🇺🇸$332 M—-225.6%+1250.4%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at X4 Pharmaceuticals, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show X4 Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about X4 Pharmaceuticals, Inc.? Suggest a correction